2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus.
It is our hope that the drug candidate can be developed into a treatment for early-stage Alzheimer’s disease.
Back